​

Vaxcyte (PCVX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

PCVX Stock Forecast

Vaxcyte (PCVX) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $77.00, with a high of $77.00 and a low of $77.00. This represents a 41.67% increase from the last price of $54.35.

$50 $63 $76 $89 $102 $115 High: $77 Avg: $77 Low: $77 Last Closed Price: $54.35

PCVX Stock Rating

Vaxcyte stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 11 Strong Sell Sell Hold Buy Strong Buy

PCVX Price Target Upside V Benchmarks

TypeNameUpside
StockVaxcyte41.67%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$77.00$77.00
Last Closing Price$54.35$54.35$54.35
Upside/Downside-41.67%41.67%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 26171--9
Dec, 25171--9
Nov, 25181--10
Oct, 25181--10
Sep, 2519---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 19, 2025David RisingerLeerink Partners$77.00$49.5355.46%41.67%
Nov 06, 2024Roger SongJefferies$146.00$106.7436.78%168.63%
Nov 06, 2024David RisingerLeerink Partners$135.00$106.7426.48%148.39%
Sep 10, 2024Salim SyedMizuho Securities$163.00$115.2841.39%199.91%
Sep 04, 2024Jason GerberryBank of America Securities$140.00$110.1527.10%157.59%
Sep 03, 2024David RisingerLeerink Partners$153.00$112.0436.56%181.51%
Sep 03, 2024Tom ShraderBTIG$160.00$110.1545.26%194.39%
Sep 03, 2024Roger SongJefferies$129.00$111.1316.08%137.35%
Sep 03, 2024Salim SyedMizuho Securities$113.00$111.091.72%107.91%
Aug 07, 2024Tom ShraderBTIG$98.00$70.5238.97%80.31%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 07, 2026NeedhamBuyBuyhold
Nov 19, 2025Leerink PartnersOutperformOutperformhold
Aug 07, 2025Cowen & Co.BuyBuyhold
Nov 06, 2024Leerink PartnersOutperformOutperformhold
Sep 04, 2024GuggenheimBuyBuyhold
Sep 03, 2024Cowen & Co.BuyBuyhold
Sep 03, 2024NeedhamBuyBuyhold
Sep 03, 2024BTIGBuyBuyhold
Sep 03, 2024JefferiesBuyBuyhold
Aug 07, 2024BTIGBuyBuyhold

Financial Forecast

EPS Forecast

$-8 $-7 $-6 $-5 $-4 $-3 $-2 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.14$-3.80----
Avg Forecast$-3.42$-3.91$-4.38$-4.63$-5.26$-3.30
High Forecast$-2.95$-3.49$-3.24$-2.78$-4.47$-3.30
Low Forecast$-3.77$-4.68$-6.15$-5.86$-7.10$-3.30
Surprise %21.05%-2.81%----

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$25.00M$97.50M$489.28M
High Forecast---$25.00M$97.50M$489.28M
Low Forecast---$25.00M$97.50M$489.28M
Surprise %------

Net Income Forecast

$-700M $-610M $-520M $-430M $-340M $-250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-402.27M$-463.93M----
Avg Forecast$-326.57M$-396.52M$-559.26M$-540.52M$-559.77M$-320.43M
High Forecast$-286.38M$-338.69M$-315.15M$-270.50M$-434.43M$-320.43M
Low Forecast$-366.77M$-454.34M$-597.93M$-569.46M$-689.91M$-320.43M
Surprise %23.18%17.00%----

PCVX Forecast FAQ

Is Vaxcyte stock a buy?

Vaxcyte stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Vaxcyte is a favorable investment for most analysts.

What is Vaxcyte's price target?

Vaxcyte's price target, set by 11 Wall Street analysts, averages $77 over the next 12 months. The price target range spans from $77 at the low end to $77 at the high end, suggesting a potential 41.67% change from the previous closing price of $54.35.

How does Vaxcyte stock forecast compare to its benchmarks?

Vaxcyte's stock forecast shows a 41.67% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Vaxcyte over the past three months?

  • January 2026: 11.11% Strong Buy, 77.78% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 11.11% Strong Buy, 77.78% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 10.00% Strong Buy, 80.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.

What is Vaxcyte’s EPS forecast?

Vaxcyte's average annual EPS forecast for its fiscal year ending in December 2025 is $-4.38, marking a 15.26% increase from the reported $-3.8 in 2024. Estimates for the following years are $-4.63 in 2026, $-5.26 in 2027, and $-3.3 in 2028.

What is Vaxcyte’s revenue forecast?

Vaxcyte's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $25M, followed by $97.5M for 2027, and $489.28M for 2028.

What is Vaxcyte’s net income forecast?

Vaxcyte's net income forecast for the fiscal year ending in December 2025 stands at $-559M, representing an 20.55% increase from the reported $-464M in 2024. Projections indicate $-541M in 2026, $-560M in 2027, and $-320M in 2028.